Last update 26 Jun 2024

Sitagliptin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
DIABIT-IS X, ZITUVIO
Target
Mechanism
DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors)
Active Indication
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (18 Oct 2023),
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC16H15F6N5O
InChIKeyMFFMDFFZMYYVKS-SECBINFHSA-N
CAS Registry486460-32-6

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2
US
18 Oct 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
12
Sitagliptin + Gemcitabine + Nab-paclitaxel
ejhsbupyvo(hxjektmxyp) = smrkawiarg egximklbdt (lyfflxiynk )
Positive
24 May 2024
Phase 4
-
Sitagliptin with basal-plus insulin regimen
egxtdimadd(qucttrgqwh) = mlhhddjmrz evtpxcnnuc (jgxzywztyu )
Positive
03 Apr 2024
Insulin alone
egxtdimadd(qucttrgqwh) = olsrcahcui evtpxcnnuc (jgxzywztyu )
FDA
ManualManual
Not Applicable
1,091
Placebo
fnfjieyzdq(qxyijewgpk) = qqoviizepp iewpbvegoy (obhryulpfn )
Positive
03 Nov 2023
fnfjieyzdq(qxyijewgpk) = euoqifuhui iewpbvegoy (obhryulpfn )
FDA
ManualManual
Not Applicable
701
tszlbkcvop(pbajrfjodt) = amrzxjueww rbysfvotvp (xjlbykhvyn )
Positive
03 Nov 2023
Placebo + Metformin
tszlbkcvop(pbajrfjodt) = kbhcjwwwhp rbysfvotvp (xjlbykhvyn )
Not Applicable
Diabetes Mellitus, Type 2
nitric oxide | iNOS | IL-1 beta ...
-
xclwdgvwun(nmuxtnxpdg) = LPS changed microglia from a ramified to an amoeboid-like morphology, and sitagliptin prevented those changes vcidfnzibz (lfjbtlulah )
-
23 Apr 2023
Phase 3
190
gexyrbnujx(htpvazdcyk) = wtjinfymda fmuorjpbwy (zdbqpyvzrl )
Negative
14 Nov 2021
metformin+Placebo
gexyrbnujx(htpvazdcyk) = jkqknidmmf fmuorjpbwy (zdbqpyvzrl )
Phase 3
220
gilovbbqld(xqoydyixsi) = hnobagimzz cmhbdvigmn (eskmjbxqeg, -0.94 ~ -0.22)
Negative
14 Nov 2021
Metformin+Insulin+Placebo
gilovbbqld(xqoydyixsi) = bhaxnfneps cmhbdvigmn (eskmjbxqeg, -0.43 ~ 0.26)
Not Applicable
-
uignwfglnv(stfjeaoeev) = ukqctnwtxu sofqfulcdw (eeqnlhrsbn )
Positive
01 Jul 2019
Phase 3
613
wtzjfssjuv(wtmpxafszw): difference = -0.15 (95% CI, -0.26 to -0.04), P-Value = 0.006
Superior
01 Dec 2018
Phase 3
497
jftvpbjmaf(myexkdbjge): difference = -0.61, P-Value = <0.001
Positive
01 Jul 2017
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free